Arbutus Biopharma (ABUS) Misses Q2 EPS by 1c

Arbutus Biopharma (NASDAQ: ABUS) reported Q2 EPS of ($0.11), $0.01 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $1.73 million versus the consensus estimate of $1.77 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• Abbott (ABT) Declares $0.63 Quarterly Dividend; 2.9% Yield
• Nvidia pitches Vera CPU to Chinese clients with August delivery target